Objective: Classical Hodgkin lymphoma shows a peak incidence at 15-35 years, and a second peak in elderly patients; however, pathological characteristics of elderly patients with classical Hodgkin lymphoma have not been analyzed enough. Methods: In a total of 154 patients with classical Hodgkin lymphoma, we analyzed the clinicopathological characteristics of classical Hodgkin lymphoma patients aged ≥40 years old, with special reference to the incidence, histopathology and outcome of patients with composite classical Hodgkin lymphoma. Results: Of 154 patients with classical Hodgkin lymphoma, 50 (32%) were ≥40 years old. The 5-year progression-free and overall survival rates were 59 and 86%, respectively. Thirty-eight patients (76%) had non-composite classical Hodgkin lymphoma, 10 patients (20%) had composite (6 simultaneous and 4 consecutive) classical Hodgkin lymphoma and B-cell non-Hodgkin lymphoma and 2 patients (4%) had methotrexate-associated classical Hodgkin lymphoma. Of 10 patients with composite classical Hodgkin lymphoma, composite lymphomas were detected throughout the staging procedure of the upper gastrointestinal tract or bone marrow in 4 patients. Fluorescence in situ hybridization revealed that the composite lymphomas of 4, 1 and 5 patients were related, unrelated and of unknown correlation status, respectively. The treatments after the diagnosis of a classical Hodgkin lymphoma component varied, and three patients died of lymphoma. Conclusions: We found that the incidence of composite classical Hodgkin lymphoma in patients ≥40 years old was 20%. Correct diagnosis and optimal treatment for patients with composite classical Hodgkin lymphoma and B-cell non-Hodgkin lymphoma is highly important in this patient population.
Introduction the five-year overall survival (OS) rate was 65% (vs. 90% in younger patients) and the HL-specific freedom from the treatment failure rate was 73% (vs. 82% in younger patients). Lower dose intensity and higher mortality rates during treatment have been suggested to be major factors for poor outcomes in elderly HL patients (2) .
Epstein-Barr virus (EBV) has been postulated to play a role in the pathogenesis and the outcome of CHL. The reported incidence of EBV positivity in CHL cases varies: 31% (≥50 years old) (3) and 34% (≥60 years old) (4) in two European studies, but up to 100% in tropical regions (5, 6) . In particular, EBV is frequently found in mixed cellularity and lymphocyte depleted subtypes (1) . The prognostic significance of EBV-association on OS in CHL cases is controversial. However, there have been several reports suggesting unfavorable OS in elderly patients with EBV-positive CHL compared with that of patients with EBV-negative CHL (3, 4, 7) . Jarrett et al. (3) reported that in patients ≥60 years old, the 5-year OS rate of patients with EBV-positive CHL was 43%, which was significantly shorter than that of patients with EBVnegative CHL (62%). Moreover, some cases of EBV-positive CHL are known to be associated with methotrexate therapy for rheumatoid arthritis (1) .
Patients with composite CHL and B-cell non-Hodgkin lymphoma [B-NHL; follicular lymphoma (FL) (8) (9) (10) , marginal zone lymphoma (MZL) (11, 12) and chronic lymphocytic lymphoma (13, 14) ] have been reported, and a correlation between the CHL and B-NHL components of some of those cases were proven genetically (8, 9, 11, 13) . However, the incidence of composite CHL and B-NHL in patients with CHL is currently not known. In addition, while the incidence of IGH/BCL2 fusion in Hodgkin/Reed-Sternberg cells by using fluorescence in situ hybridization (FISH) and/or chromogenic in situ hybridization analyses has been reported to be higher in composite CHL and FL cases (100%, 3/3 cases) than in non-composite CHL cases (9%, 1/11 cases); however, the number of analyzed cases was relatively small (15) . Moreover, the most appropriate management of patients with composite CHL is yet to be defined.
The aim of this study was to identify the clinicopathological characteristics of CHL patients aged ≥40 years old, with special reference to the incidence, histopathology and the outcome of patients with composite CHL.
Patients and methods

Patient selection
This study included 154 consecutive patients with CHL who were treated at the National Cancer Center Hospital, Tokyo, Japan, between 1998 and 2013. All patients were negative for anti-human immune deficiency virus antibody in the serum. Patients ≥40 years old were selected and analyzed clinicopathologically. Clinical information was obtained from their medical records. The Ann Arbor system was used for staging, and the staging procedures included bone marrow aspiration or biopsy, endoscopy of the upper gastrointestinal tract, whole-body computed tomography and optional positron emission tomography. Most of the patients (92%, 33/36) received adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). The median followup period was 57 months (range, 10-171 months). Informed consent was obtained from each patient, and the study was approved by the institutional review board of the National Cancer Center.
Morphological review
The biopsy or operation materials were fixed in 10% neutral-buffered formalin, embedded in paraffin, cut into 4 μm thick sections and stained with hematoxylin and eosin for histopathological evaluation. 
Immunohistochemical, in situ hybridization, and interphase FISH analyses
Immunohistochemical analysis of formalin-fixed, paraffin-embedded tissues was performed using a panel of monoclonal antibodies. Sections 4 μm thick were cut from each paraffin block, deparaffinized and incubated at 121°C in citrate buffer (pH 6.0) for 10 min for antigen retrieval. Antibodies against the following antigens were used: CD3 (PS1, 1:25; Novocastra, Newcastle upon Tyne, UK), CD5 (4C7, 1:100; Novocastra), CD10 (56C6, 1:100; Novocastra), CD15 (MMA, 1:100; Becton Dickinson, Tokyo, Japan), CD20 (L26, 1:200; Dako, Glostrup, Denmark), CD30 (Ber-H2, 1:100; Dako), CD79a (JCB117, 1:100; Dako), cyclin D1 (SP4, ready for use; Nichirei, Tokyo, Japan), BOB1 (sc-955, 1:200; Santa Cruz, Dallas, Texas), OCT2 (sc-233, 1:1000; Santa Cruz) and PAX5 (24/Pax-5, 1:100; Becton Dickinson). In situ hybridization with an EBV-encoded small nuclear early region (EBER)-1 probe (Dako) was performed to detect possible EBV infection.
Sections 4 μm thick were cut from each paraffin block and used for FISH analysis. A LSI IGH Spectrum Green/LSI BCL2 Spectrum Orange Dual Fusion Translocation Probe (Vysis, Downers Grove, IL) was used to detect the IGH/BCL2 fusion. The fusion gene was identified as previously described (16) . In addition, a LSI MALT1 Dual Color Break Apart Rearrangement Probe (Vysis) was used to detect the MALT1 split. Moreover, FISH analysis for HRS cells was performed by Fluorescence Immunophenotyping and interphase Cytogenetics as a Tool for the Investigation Of Neoplasm (FICTION) method, as previously described (17) .
Statistical analysis
The patient survival rates were estimated using the Kaplan-Meier method. Univariate analyses were performed using the log-rank test. Differences between groups were considered significant when the P value was ≤0.05. Progression-free survival (PFS) duration was calculated from the initial date of treatment to the date of disease progression, relapse or death from any cause. OS duration was calculated from the date of diagnosis to the date of death from any cause.
Results
Distribution of CHL according to age, composition and methotrexate status
The distributions of all 154 patients with CHL according to age, composition of B-NHL and methotrexate status are summarized in Table 1 . Fifty patients (32%) were ≥40 years old and 104 patients (68%) were <40 years old. Among patients ≥40 years old, 38 (76%) had non-composite CHL, 10 (20%) had composite (simultaneous or consecutive) CHL and B-NHL and 2 (4%) had methotrexate-associated CHL (both were EBER1-positive mixed cellularity subtype). Conversely, in patients <40 years old, all 104 patients had non-composite CHL, indicating that composite CHL was observed only in patients ≥40 years old.
Subtypes of non-composite CHL and EBER1 status in patients ≥40 years old
The correlations between histological subtypes of non-composite CHL and EBER1 status in the 38 patients ≥40 years old are summarized in Table 2 . Of the 34 patients with information available regarding the EBER1 status, 28 patients (82%) had EBER1-negative CHL and 6 patients (18%) had EBER1-positive CHL. Of the 28 EBER1-negative CHL cases, the histological subtypes varied; however, of the 6 EBER1-positive CHL cases, with the exception of one case of the nodular sclerosis subtype, only the mixed cellularity subtype was observed.
Clinical characteristics and outcomes of CHL patients ≥40 years old
The clinical characteristics of the 36 patients with CHL aged ≥40 years old with available clinical information are summarized in Table 3 . Overall, the 5-year PFS and OS rates were 59% and 86%, Figure 2 . Representative case of composite CHL in the lymph node and follicular lymphoma (FL) in the duodenum (Case 3). CHL, mixed cellularity component, was seen in the lymph node specimen (A, hematoxylin and eosin [HE], ×400). The Hodgkin/Reed-Sternberg cells were positive for CD30 (B, ×400) and PAX5 (C, ×400), but negative for CD20 (D, ×400). A FL component was simultaneously seen in the duodenum (E, HE, ×100). It was positive for CD10 (F, ×100) and Bcl-2 (G, ×100). Both lymphomas were positive for IGH/BCL2 fusion.
respectively. The stage of CHL was a marginally significant predictor of PFS (P = 0.048). On the other hand, there were no significant predictors of OS.
The 5-year PFS and OS rates of the 6 patients with EBER1-positive non-composite CHL were both 100%, although it should be noted that the number of patients was small. The PFS of the 6 patients with EBER1-positive CHL tended to be better than that for the 20 patients with EBER1-negative CHL and 10 patients with composite CHL (P = 0.068, Fig. 1A) . Moreover, patients with composite CHL tended to show shorter OS; however, it was not statistically significant (P = 0.335, Fig. 1B) .
Description of 10 patients with composite CHL
The descriptive information of the 10 patients with composite CHL is summarized in Table 4 . Six patients had simultaneous CHL and B-NHL, while four patients had consecutive CHL and B-NHL. The histology of B-NHL was FL in five patients, FL and DLBCL in one patient, MZL in three patients and MZL and DLBCL in one patient. In 4 out of the 10 patients, the composite lymphomas were detected throughout the staging procedure. In Case 2, a FL component was detected in the bone marrow, whereas in Cases 3 and 4, a FL component was detected in the duodenum during screening of the upper gastrointestinal tract (Fig. 2) . In Case 5, a CHL component was detected in the bone marrow.
By using FISH and FICTION analyses, the composite lymphomas of four patients were found to be related; in these patients, both types of lymphomas showed IGH/BCL2 fusion. The four patients corresponded to 67% (4/6) of the patients with composite CHL and FL. In five patients, no correlation between CHL and B-NHL was proven, but correlation was still considered a possibility clinically. In the three (Cases 4, 5 and 8), advanced stage low-grade B-cell lymphoma preceded CHL and CHL occurred in the lesion. One (Case 9) had CHL followed by advanced stage MZL. In the remaining case (Case 6), MZL and CHL occurred in close association. All five cases were speculated to have an association between CHL and low-grade B-cell lymphoma based on their clinical presentation. In Case 10, CHL and MZL were determined to be unrelated, as the CHL was negative for the MALT1 split whereas the MZL was positive. Three out of 4 patients (75%) whose B-NHL contained a MZL component did not show positive findings for the MALT1 split.
The treatments after the diagnosis of CHL were as follows: ABVD (n = 3); rituximab (R)-ABVD (n = 2); R-cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) followed by ABVD (n = 1), R-cyclophosphamide, vincristine, procarbazine and prednisolone (C-MOPP) followed by ABVD (n = 1), C-MOPP followed by ABVD (n = 1), R-CHOP (n = 1) and C-MOPP (n = 1). Two patients received irradiation.
Three of the 10 patients died of lymphoma (Cases 5, 7 and 8). Cases 5 and 8 showed bone marrow involvement of CHL (Fig. 3) , while Cases 7 and 8 had simultaneous high-grade B-cell lymphoma: Case 7 had simultaneous DLBCL and Case 8 had simultaneous B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and CHL (Fig. 3) . Similarly, Case 6 also had simultaneous DLBCL and CHL; however, this patient showed a favorable outcome.
Discussion
We here analyzed the clinicopathological characteristics of patients with CHL aged ≥40 years old, with special reference to patients with composite CHL and B-NHL. In the present study, the incidence of patients aged ≥40 years old was 32% out of a total of 154 patients with CHL. Engert et al. (2) from the German Hodgkin Study Group reported that in patients with CHL aged ≥60 years old, the 5-year OS rate was 65%. In the present study conducted for patients ≥40 years old, the 5-year PFS and OS rates were 59 and 86%, respectively. In this study, the incidence of composite CHL and B-NHL was 20% in a total of 50 patients with CHL aged ≥40 years old. Interestingly, composite CHL was observed only in patients ≥40 years old. In 4 out of 10 patients with composite CHL, the second lymphoma was detected in the bone marrow or duodenum during the staging procedure. Therefore, in CHL patients aged ≥40 years old, the presence of composite B-NHL components should be suspected and analyzed carefully.
By using FISH and FICTION analyses, the composite lymphomas of four patients (40%) were found to be cytogenetically related, and those of one patient (10%) were unrelated. Conversely, no correlation was proven for five patients, although it was considered a possibility clinically. The incidence of IGH/BCL2 fusion in FLs has been reported to be 60% in Japan (15) , and that of MALT1 translocation in MZL as 7-31% in the stomach, 0-22% in the skin and 0% in the lymph nodes (1). Accordingly, even if the two components of composite CHL and B-NHL are related, their correlation may not be revealed by FISH analysis in ∼40% of the composite CHL and FL cases and in the majority of composite CHL and MZL cases. Although analysis using microdissection and sequencing is better for analyzing the correlation between CHL and B-NHL components (8, 9, 11, 13) , the use of FISH and FICTION analyses is easier for detecting their correlation in routine examinations.
For patients with composite CHL and high-grade B-cell lymphoma, treatment for high-grade B-cell lymphoma was conducted at first, whereas for patients with composite CHL and low-grade B-cell lymphoma, treatment for CHL was conducted at first. In the present study, three patients died of lymphoma: one patient with bone marrow involvement of CHL, one patient with high-grade B-cell lymphoma (DLBCL) and one patient with a combination of both. Hence, bone marrow involvement of CHL and/or coexistence of a high-grade B-cell lymphoma component might be poor prognostic factors for patients with composite CHL. The optimal treatment for these patients needs to be defined in the future.
Furthermore, in patients with CHL aged ≥40 years old, 18% of the cases were EBER1-positive and non-composite. Elderly patients with EBV-positive CHL have been reported to show unfavorable overall survival (3, 4, 7) , although this correlation is controversial when taking into account patients of all ages. In the present study, both the 5-year PFS and 5-year OS rates of 6 patients with EBER1-positive CHL were 100%; in other words, it is unlikely that EBER1-positivity was an unfavorable predictor of PFS and OS in this study. However, it should be noted that the number of patients was small.
In conclusion, we found that the incidence of composite CHL was 20% in patients with CHL aged ≥40 years old. Our results suggest that correct diagnosis and appropriate treatment for composite CHL and B-NHL is highly important in patients ≥40 years old.
